# Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

> **NCT02227108** · PHASE2 · TERMINATED · sponsor: **MedImmune LLC** · enrollment: 37 (actual)

## Conditions studied

- B-Cell Pediatric ALL

## Interventions

- **DRUG:** Moxetumomab Pasudotox

## Key facts

- **NCT ID:** NCT02227108
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** The study was terminated prior to a planned interim analysis based on lack of required efficacy in the first 32 participants enrolled.
- **Last updated:** 2017-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227108, "Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02227108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*